• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    TaiMed Biologics

    Federal Equipment Company

    Lannett CDMO

    Quotient Sciences

    U.S. Pharmacopeia (USP)
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    TaiMed Biologics

    Federal Equipment Company

    Lannett CDMO

    Quotient Sciences

    U.S. Pharmacopeia (USP)
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Transitioning from Clinical Production to Commercial Manufacturing

    Cell and gene therapy facilities face a unique set of challenges as they scale towards commercial production and require equally unique solutions.

    Transitioning from Clinical Production to Commercial Manufacturing
    Peter Walters, Lead Process Engineer, CRB USA11.20.19
    Cell and gene therapy companies have one major thing in common with other types of biopharmaceutical firms: they need to move fast.

    As the first few advanced therapy medicinal products (ATMPs) gain regulatory approval, and as patients with previously incurable diseases find new reasons to hope for effective treatment, the pressure to move quickly can bear down with enormous force. Across every biopharmaceutical area, the years spent progressing through preclinical and clinical studies are years of colossal pre-profit spending. That slender window between the first day of commercial manufacturing and the last day of a patent’s term of protection is often a company’s first and only opportunity to slingshot themselves back into the black. Getting there as soon as possible, while maintaining regulatory compliance and ensuring the safety and care of the patient population, is a central preoccupation.

    This is where many of the similarities end. Cell and gene therapy facilities face a unique set of challenges as they scale towards commercial production, and they require equally unique solutions. While other types of biopharmaceutical facilities can follow a template as they grow, calculating their required footprint and equipment capacity based on well-established economies of scale, ATMP facilities have to invent their own way forward.

    Nothing is templated. Everything is novel. New generations of technology emerge almost monthly. Open, operator-driven processes are the norm, making up for a limited availability of closed, automated cell and gene therapy technologies on the market today. And because those open processes support the production of highly personalized virus and viral vector products for very small patient populations (as small as just one patient, in the case of autologous production), they can vary greatly even within the same facility, and they require rigorous biosafety design measures. Under these unique and variable conditions, scaling up is very difficult, and scaling out quickly becomes prohibitively expensive.

    Many facilities, under pressure to move quickly, put off planning for this transition until well into their Phase II clinical studies. By then, the opportunity to proactively prepare for commercial-scale manufacturing has passed. Facilities are left trying to forcibly stretch small-scale R&D processes to commercial size, leading to immense overhead, lost efficiency, and a strained, unsustainable labor model.

    There is a solution: start planning for commercialization as early as the preclinical testing phase. This is a daunting prospect for some; it means siphoning time and money away from today’s priorities in order to prepare for tomorrow’s unknowns. Making room for such an exercise during those pre-profit years is difficult, but it’s necessary. Without the early intervention of a diligent, expert-led plan for commercial scale-out, it won’t matter how fast you get there—you’ll be met with costly, time-consuming challenges that could dismantle all of your early progress.

    The Transition from Research to Commercial Manufacturing
    As companies work to perfect their process design in the R&D phase, many believe that scaling to commercial production based on current good manufacturing practices (CGMPs)  will mean simply transferring that same design into a larger blueprint. The trouble is, the R&D process in ATMP manufacturing isn’t the pliable muscle that some believe it to be; it can’t just extend itself from a small patient population to a large one without risking a lot of integrity and becoming exceedingly inefficient. That’s because the goals of each phase in your product’s development lifecycle aren’t the same.  

    In the research phase, you’re trying things. You need to carefully parse what works from what doesn’t. You need to test different medias, study the data and draw conclusions about the best way forward. In many facilities, this is achieved through the efforts of human operators, working with open flasks in high-environmental-classification biosafety cabinets. Maybe you have two people doing it all at first, working on developmental lots with a transitional process. As you progress into preclinical testing and early clinical studies, you might scale that model to serve ten people or support a single process equipment train—still manageable, and still largely based on an agenda of investigation and data gathering. Later clinical testing might drive you to ten patients a month. Most companies can manage this scale-up by simply carrying more of their initial process.

    In the commercial phase, however, your focus shifts. You need to think about CGMP compliance while growing your throughput as quickly as possible. That means safely scaling that ten-patient process to 100, or 150, or 200 patients a month. It also means scaling your QC testing lab to ensure the integrity of your product and to keep you on the right side of an increasingly active and ever-evolving regulatory body.
    Suddenly, the labor model that so beautifully served your R&D activities starts to break down. Where will you find the hundreds of workers required to scale out your operator-driven process? Even if you do find them, where will you put them? Where will they park their cars, eat their lunch, and hold their meetings? Are they skilled? Are they trained? In a field like ATMP manufacturing, where the technology is so new and the processes so variable, will the meteoric growth of your workforce put the quality of your product at risk? Who will scale your SOPs, and who will supervise their application and proactively correct any deviations?

    The challenges of finding and onboarding and supervising all of those workers is only the thin end of the wedge. You’ll also need to face the problem of scaling that open process itself. It worked well during your R&D activities, allowing operators to nimbly assess and adjust their materials, but it will be very expensive to scale. First, there’s the cost of adding adequate facility footprint to support your production trains or suite modules—a huge undertaking, especially if you don’t get started until Phase II clinical studies, when it’s difficult to quickly and retroactively right-size your facility for commercialization. Then there’s the cost of constructing, powering and maintaining all those clean rooms to support your open process. Add the cost of building transitional airlocking space as well as QC labs for full-release testing. By the time you’re through, you’re looking at a per-square-foot price tag that could turn even the most well-funded project executives an alarming shade of white.

    A labor model and a process that are difficult to scale: these are the linchpin challenges of many cell and gene therapy projects as they mature from clinical testing to commercial manufacturing. Overcoming these challenges by shifting from an open, operator-centric model to one that’s closed, automated, and scalable takes both ingenuity and time. Doing it well means starting the process early, and it requires two key skills: an ability to imagine the future, and a willingness to investigate the best and most efficient way to get there.

    Begin with the End in Mind
    Start by dropping the words “we’ll figure it out later” from your vocabulary. Instead, develop a company philosophy predicated on flexibility, curiosity, and constant, proactive improvement. That philosophy will get baked into every aspect of your facility as you grow, and will guide you as you set the stage for your future commercial success.

    “Setting the stage” means continuously investigating new CGMP-rated technologies, particularly technical models that support automation. Look for opportunities to integrate automated technology into your process right now, while that process is still malleable enough to accommodate it. You may not end up with a fully automated system, but you can come close, if you plan appropriately. This can apply across your entire organization, not just in the production suite. Automation in QC testing, for example, can help reduce bottlenecks and ease the strain of finding more skilled workers and growing your footprint.
    Automation in your warehousing process could have enormous impacts too, ensuring that materials are tracked, stored and released with fewer risks and a level of speed and integrity not possible from human workers alone.

    Next, you need to assess every purchase decision with a closed, commercial-scale process in mind, even if that process isn’t possible with today’s technology. New technical solutions designed for closed ATMP manufacturing are poised to emerge on the market any day, and when they do, they could have a tremendous impact on process and facility design. Purpose-built isolator technology and other innovations will mean you’ll no longer have to depend quite so heavily on massive clean rooms, transitional airlocks, and unidirectional flow systems to maintain regulatory compliance. This will liberate a large swathe of your facility’s footprint for other, more efficient uses.

    You can start planning for that eventuality today by building flexibility into your process design and purchasing decisions. For example, if you need to acquire flasks to support your R&D activities, look for a product design with a correlative that will work in a closed system. You’ll be grateful for this foresight later on, when you begin to transition to a closed process at the commercial scale. Do this with every process-related decision to help future-proof your facility.

    You may discover that parts of your process simply can’t be closed, ever. Even that discovery, if made early enough, is useful. It means you can plan around the open elements of your process accordingly. This is how the best facilities make efficient and measurable progress towards profitability: they don’t wait for a magic bullet to strike. Instead, they go looking for one. From day one, they make decisions that promote flexibility and anticipate possible future needs and opportunities.

    Find Efficiencies Where You Can
    Moving towards commercial manufacturing means taking on larger patient populations, but that doesn’t have to require a much bigger facility. Not if you’ve worked early in your process to adopt systems that integrate vertically, allowing you to expand your pipeline without necessarily expanding your footprint.

    Cell and gene therapy facilities with relatively modest biosafety level (BSL) requirements can manage this by designing large ballroom-type operating areas. Each workstation in the ballroom can be equipped with everything needed for a closed, A-to-Z process. Operators aren’t transporting materials from one place to another, risking contamination and losing valuable time; instead, they’re stationary, completing the whole process from start to finish right where they are. This allows for a dense, efficient use of your facility’s footprint; you can stack these stations vertically, reducing overhead costs and supporting a labor model that scales along with your patient population.

    Facilities designed to accommodate such a vertical integration strategy from day one have the best chance of succeeding. It’s not impossible to modify your facility later on, but a retrofit is much harder to undertake than a proactive design. It costs more, it may impact your regulatory filings, and it often requires a full-system shut down for the duration of construction work, bringing production to its knees. Proper planning from the outset mitigates against such risks and ensures continual operations as you scale out to commercial manufacturing.

    Even facilities whose elevated biosafety levels prevent vertically integration can de-risk their scale-out strategy by scoping future production needs early in the clinical testing process. This means forecasting your requirements for segregated personnel, material and waste flows, and full-room fumigation at a commercial scale. Assess every element closely, right down to the quality of construction materials and door seals. These details, if carefully tended in a facility’s initial design, can mean the difference between a smooth transition to commercialization and a disaster.

    A Commercial State of Mind
    Your facility represents a new breed of biotechnology company. It looks and operates differently from facilities in more established submarkets, which makes planning for your future scale-out a complex exercise. It’s possible that the technology you’ll be using five years from now hasn’t even been alpha tested today, or that the closed processes you’ll introduce for commercial manufacturing aren’t possible in your present-day research lab. There are no absolutes, and there are no bright lines marking the way forward. But there is this: the possibility of curing a previously incurable disease and dramatically impacting the lives of patients who otherwise face an uncertain future. With that prospect as your talisman, and an expert-driven and proactive approach to planning for a changeable future, you can succeed.

    The key is flexibility. By approaching the question of commercial scale-out with a philosophy that embraces (rather than fears) the unknown, you can prepare yourself for whatever comes next. 


    Peter Walters is Lead Process Engineer with CRB USA. He can be reached at peter.walters@crbusa.com.
    Related Searches
    • scale-up
    • equipment
    • biotechnology
    • capacity
    Suggested For You
    Softweb Solutions Softweb Solutions
    When Life Gives You Lemons…Raise Your Drug Prices When Life Gives You Lemons…Raise Your Drug Prices
    The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing
    Lonza Selects Cryoport as Preferred Partner Lonza Selects Cryoport as Preferred Partner
    Parexel Expands SCRS Collaboration Parexel Expands SCRS Collaboration
    Vetio Animal Health Vetio Animal Health
    Eisai, Biogen Discontinue Phase III Alzheimer Eisai, Biogen Discontinue Phase III Alzheimer's Trials
    Bayer Bayer
    Contract Packaging Trends Contract Packaging Trends

    Related Buyers Guide Companies

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Scale-up/Technology Transfer
      The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing

      The Pain-Free Guide: Transitioning from Clinical Production to Commercial Manufacturing

      Cell and gene therapy facilities face a unique set of challenges as they scale towards commercial production and require equally unique solutions
      Peter Walters , Lead Process Engineer, CRB USA 11.11.19


    • Breaking News | Cold Chain Management | Industry News | Logistics | Supply Chain
      Lonza Selects Cryoport as Preferred Partner

      Lonza Selects Cryoport as Preferred Partner

      Will work to remove the supply chain hurdles faced by developers of Cell & Gene Therapies
      11.08.19

    • Clinical Trials | CRO News
      Parexel Expands SCRS Collaboration

      Parexel Expands SCRS Collaboration

      Key initiatives will focus on improving the patient experience in clinical trials
      10.31.19

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    AkzoNobel Shares Sustainable Architectural Solutions at Conference
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Stoelzle Glass Group Names New CEO
    Happi

    Latest Breaking News From Happi

    The Estée Lauder Companies Launches 2023 Breast Cancer Campaign
    BASF Personal Care Introduces New Cosmetic Ingredient
    Breakfast with Oral Care Benefits?
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Climate Targets Validated by SBTi
    ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
    Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
    SCHOTT Strengthens Glass Substrate Portfolio

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login